Molecular Targeting Technologies Inc Thomas Jefferson University and North China Pharmaceutical Co Ltd Announced the Chinese Approval for a Rabies Drug
Molecular Targeting Technologies, Inc. (MTTI) announced that the Chinese NMPA has approved a rabies virus neutralizing, fully human antibody, Ormutivimab for post-exposure prophylaxis. Clinical results showed Ormutivimab to be safe and effective, achieving its main and secondary efficacy endpoints after a single injection in exposed individuals. Ormutivimab was invented at Thomas Jefferson University and licensed to MTTI which has conducted trials in China in partnership with the North China Pharmaceutical Co., Ltd (NCPC).
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
